Navigation Links
SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
Date:7/21/2010

CALGARY and CAMBRIDGE, MA, July 21 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a leading developer of biosimilar drug candidates, high-value proteins and oils utilizing its novel plant expression systems, today announced that Rick Pierce has joined the Company as President of US and International Operations. Mr. Pierce will open a US office in Cambridge, Massachusetts which will offer the Company a broader market to better exploit its technology platform and access to US and International markets.

Mr. Pierce joins SemBioSys after four successful years with Javelin Pharmaceuticals (NYSEamex:JAV), which was recently acquired by Hospira, Inc. (NYSE: HSP), where he served as Vice President, responsible for leading the firms investor relations and business development initiatives. Mr. Pierce played a significant role in the business development discussions which led to the Hospira transaction. Prior to Javelin, Mr. Pierce was a senior executive at two Nasdaq listed biotechnology firms for eight years including experience in doing business in China and had previously spent fourteen years with Wall Street firms including Merrill Lynch and Lehman Brothers. During his investment career, Mr. Pierce specialized in sales, trading and investment banking of healthcare and biotechnology equities. Mr. Pierce has been involved in a number of highly successful IPO's, secondary offerings, private placements, mergers and acquisitions and pharmaceutical licensing transactions.

Earlier this year, well known Canadian biotech analyst Karen Boodram joined the firm as Vice President of Business Development. Further, the Company has promoted Dr. Joe Boot
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SemBioSys updates progress on Apo AI(Milano)
2. SemBioSys securityholder vote to be held December 18, 2009 with a record date of November 16, 2009
3. SemBioSys announces third quarter 2009 financial and operational results
4. SemBioSys provides an update on Botaneco
5. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
6. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
7. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
8. SemBioSys provides update on insulin program
9. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
10. SemBioSys announces senior management changes
11. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... LANSING, Mich. , Aug. 27, 2015  Neogen ... has acquired the stock of United Kingdom ... supplier of microbiological culture media and diagnostic systems. ... has grown into a leading provider of microbial testing ... and clinical testing markets. The company currently sells into ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... in Personalized Medicine, recently presented new data on the relationship of genetics and ... 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, ...
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... LYNBROOK, N.Y., Sept. 11 BioSpecifics Technologies Corp. ... in class collagenase-based products, today announced that BioSpecifics, President, Tom ... Biotech Industry" Conference on Wednesday, September 16, 2009, at 9:00 ... in New York, NY. , , A ...
... September 11 , - ThromboGenics, ... ThromboGenics NV (Euronext Brussels: THR), a ... for eye,disease, vascular disease and cancer, announced today that it ... and "Licensing Deal of,the Year" awards at the Scrip Awards ...
... , , , HORSHAM, Pa., ... it received a Complete Response letter from the U.S. Food and ... DOXIL (doxorubicin HCI liposome injection) in combination ... metastatic breast cancer. , , Centocor ...
Cached Biology Technology:ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 2ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 2Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 5
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... WASHINGTON -- Scientists and engineers from around the world ... gather to discuss recent advances in optics and photonics ... of light -- affecting renewable energy and environmental research. ... Optics and Photonics Congress: Renewable Energy & the Environment, ...
... environmental consciousness, many buildings are being outfitted to "go green." ... Elizabeth Demaray, an associate professor of fine arts, is cultivating ... counteract the lack of native vegetation found in the city. ... New York,s Art in Odd Places Festival from Oct. 1-10 ...
... 25, 2011 Eighteen leading industry speakers will present ... on November 14-15, 2011 in Philadelphia. Nearly 100 IRT ... the major shift taking place in clinical trials - ... Many bio/pharmaceutical companies look to mitigate delays, ...
Cached Biology News:Space debris, more efficient LEDs, and thinner, cheaper solar cells 2Space debris, more efficient LEDs, and thinner, cheaper solar cells 3Space debris, more efficient LEDs, and thinner, cheaper solar cells 4Space debris, more efficient LEDs, and thinner, cheaper solar cells 5Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
... One-Step Kit is the ultimate in ... It has been specifically designed to ... Reverse-iT™ One-Step Kit combines the unique ... Thermoprime Plus DNA Polymerase to provide ...
... Protein A and Protein G bind specifically ... Protein A and Protein G conjugates are ... immunoglobulins (antibodies) and immunoglobulin subtypes from serum, ... other biological fluids. These reagents are also ...
... Receptor (AR) Competitor Assay Kits provide a ... screening potential AR ligands using fluorescence polarization ... binding domain protein tagged with His and ... fluorescent androgen ligand (Fluormone AL Green in ...
... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
Biology Products: